ClinicalTrials.gg
CompletedNCT07343323Updated Jan 15, 2026

A First-in-Human Study of KINE-101 in Healthy Volunteers

A Phase 1 interventional study of KINE-101 and Placebo in Healthy Volunteers, sponsored by Kine Sciences Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Kine Sciences Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 9 months ago, and no results have been posted to the registry.
  • Registered 4 years 1 month after the study started (first participant enrolled Nov 2021, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study that evaluates the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous (IV) and subcutaneous (SC) formulations of KINE-101 in healthy volunteers at a single study center. Five cohorts of eight subjects each (six receiving KINE-101 and two receiving placebo) are admitted on Day -1, receive a single dose of investigational medicinal product (IMP) on Day 1, and remain in-house until Day 3, followed by outpatient visits on Days 7, 14, 28, and 42. Sentinel dosing applies in the first sub-cohort of each cohort: two sentinel subjects are dosed at least 10 minutes apart, and if no safety concerns arise during the 48-hour post-dose evaluation period, the remaining subjects in the cohort are subsequently dosed. Dosing in the second sub-cohort also occurs at intervals of at least 10 minutes. Four cohorts receive the IV formulation, with doses escalating from 10 mg up to an anticipated maximum of 300 mg. To compare relative bioavailability and characterize PK after subcutaneous administration, one SC cohort receives a single 96.8 mg dose. The number of cohorts and dose progression depend on emerging safety and PK data. Decisions to escalate, repeat, or modify dose levels are made by the Safety Review Committee (SRC), and additional cohorts may be added if deemed necessary.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Kine Sciences Co., Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed IRB-approved before any screening procedures.
  • Healthy subjects with no illness or disease based on medical history, physical exam, , and lab tests.
  • Males and females aged 18-55 years at screening.
  • Nonsmokers or no nicotine use for ≥1 year; urine cotinine \<200 ng/mL at screening and admission.
  • 18.5-30.0 kg/m² and body weight ≥50 kg at screening.
  • Suitable veins for venipuncture/cannulation.
  • Able to fast overnight (≥10 hours).
  • Male subjects agree to use condoms during intercourse and for 1 month after last IMP dose.
  • Male subjects must not donate sperm from dosing day until 1 month after last IMP dose.
  • Female subjects must be of non- ( ≥12 months with FSH >40 IU/L or surgical sterilization such as hysterectomy, tubal ligation, bilateral oophorectomy/salpingectomy).

Exclusion criteria

Exclusion Criteria:

  • Received an medicinal product (IMP) within 30 days or 5× half-life before first IMP administration.
  • History of alcohol abuse within 2 years, weekly intake >21 units, or positive alcohol test at screening/admission.
  • Current smokers or nicotine use within 12 months; positive urine cotinine at screening/admission.
  • abnormal labs: , AST, or total > (or >1.5×ULN if Gilbert's), serum creatinine >ULN, \<80 mL/min/1.73 m², abnormal TSH, or other clinically relevant abnormal values.
  • Positive drug abuse test at screening or admission.
  • Positive , anti-, or antibody at screening.
  • Clinically significant psychiatric, cardiovascular, renal, hepatic, or chronic respiratory disease, including arrhythmia.
  • Supine BP \<90 or >140 mmHg systolic, or \<50 or >90 mmHg diastolic after 5 minutes supine.
  • Supine pulse \<50 bpm or >100 bpm after 5 minutes supine.
  • Personal or family history of long syndrome, sudden cardiac death, or hERG mutation.
  • Severe adverse reaction or to any drug or .
  • Blood donation or loss >400 mL within 3 months or below normal limits.
  • Use of prohibited medications, OTC drugs, herbal remedies, or supplements within 28 days before IMP administration.
  • Received live or attenuated vaccines or systemic within 3 months prior to first IMP dose.
  • Conditions interfering with drug absorption, distribution, metabolism, or excretion.
  • Employees of sponsor/CRO or close relatives involved in the study.
  • Unable to communicate meaningfully with study staff.
  • QTcF >450 ms at screening or admission.
  • Significant liver impairment or abnormal conjugated/direct bilirubin >ULN.
  • Consumption of methylxanthines (tea, coffee, chocolate), quinine-containing drinks, grapefruit, Seville oranges, poppy seeds, or alcohol within protocol-defined windows before IMP administration.
  • Investigator judges subject unfit for any reason.
  • Positive SARS-CoV-2 RT-PCR within 4 weeks prior to screening.
  • COVID-19 symptoms within 14 days prior to screening.
  • Severe COVID-19 history (e.g., ECMO, mechanical ventilation).
  • Unable to attend in-person visits per site COVID guidelines.
  • Scheduled to receive COVID-19 vaccination within 2 weeks before or after IMP administration.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    KINE-101

    Drug: KINE-101

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • KINE-101 injection, 12.5 mg/mL, administered once either intravenously (10 mg, 30 mg, 100 mg, or 300 mg) or subcutaneously (96.8 mg) on Day 1, depending on cohort.

  • DrugPlacebo

    Sterile 0.9% sodium chloride solution, administered once intravenously or subcutaneously on Day 1, matching the route of the investigational product.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Incidence, severity, and relationship of treatment-emergent adverse events following single ascending doses of KINE-101.

    Time frame: Day 1 to Day 42

  2. Number of Participants with Clinically Significant Abnormal Hematology

    Count of participants with clinically significant abnormal hematology findings (e.g., white blood cell count, hemoglobin, platelet count), as defined per protocol.

    Time frame: Day 1 to Day 42

  3. Number of Participants with Clinically Significant Abnormal Clinical Chemistry

    Count of participants with clinically significant abnormal clinical chemistry findings (e.g., ALT, AST, creatinine), as defined per protocol.

    Time frame: Day 1 to Day 42

  4. Number of Participants with Clinically Significant Abnormal Urinalysis

    Count of participants with clinically significant abnormal urinalysis findings (e.g., bilirubin, glucose, pH and specific gravity), as defined per protocol.

    Time frame: Day 1 to Day 42

  5. Number of Participants with Clinically Significant Abnormal Vital Signs

    Count of participants with clinically significant abnormal vital sign findings (e.g., systolic and diastolic blood pressure, pulse, body temperature, respiratory rate), as defined per protocol.

    Time frame: Day 1 to Day 42

  6. Number of Participants with Clinically Significant Abnormal Electrocardiogram

    Count of participants with clinically significant abnormal 12-lead electrocardiogram findings (e.g., PR interval, QRS interval, QT interval), as defined per protocol.

    Time frame: Day 1 to Day 42

  7. Number of Participants with Clinically Significant Abnormal Physical Examination

    Count of participants with clinically significant abnormal physical examination findings, as defined per protocol.

    Time frame: Day 1 to Day 42

  8. Local Tolerability and Injection/Infusion Site Reactions

    Local tolerability and pain assessed using the Numerical Rating Scale (NRS; 0 = no pain, 10 = worst possible pain). Higher scores indicate worse outcomes, as defined per protocol.

    Time frame: Day 1 to Day 42

Secondary outcomes

  1. Peak Plasma Concentration of KINE-101 (Cmax)

    Maximum observed plasma concentration of KINE-101.

    Time frame: From predose on Day 1 through 24 hours postdose (Day 2)

  2. Time to Peak Plasma Concentration of KINE-101 (Tmax)

    Time to reach the maximum observed plasma concentration of KINE-101.

    Time frame: From predose on Day 1 through 24 hours postdose (Day 2)

  3. Area Under the Plasma Concentration-Time Curve to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration-time curve of KINE-101 from predose to the time of the last quantifiable concentration.

    Time frame: From predose on Day 1 through 24 hours postdose (Day 2)

  4. Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau)

    Area under the plasma concentration-time curve of KINE-101 from predose over the dosing interval following single ascending doses.

    Time frame: From predose on Day 1 through 24 hours postdose (Day 2)

  5. Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUCinf)

    Area under the plasma concentration-time curve of KINE-101 from predose extrapolated to infinite time.

    Time frame: From predose on Day 1 through 24 hours postdose (Day 2)

Other outcomes

  1. Pharmacodynamics of KINE-101 following single ascending doses

    Pharmacodynamic assessments include changes from baseline in cytokines (such as IL-6, IL-10, CXCL13, IgM, IgG) and immunophenotyping markers (such as CD4+, CD25+, FoxP3+, CD39high, CTLA-4+, CD69+) to evaluate target engagement and explore PK/PD relationships.

    Time frame: From predose on Day 1 through Day 28

07

Study locations

1 site
  • Parexel International
    Baltimore, Maryland 21225, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jan 2023, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Jan 15, 2026
StartActual
Nov 5, 2021
Primary completionActual
Jan 31, 2023
CompletionActual
Jan 31, 2023
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07343323
Lead sponsor
Kine Sciences Co., Ltd.
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Nov 5, 2021
Primary completion
Jan 31, 2023
Completion
Jan 31, 2023
Last update
Jan 15, 2026

Study contacts

Hanna Park
study director · Kine Sciences Co., Ltd.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KINE-101

Start the discussion